A blood based biomarker identifying early Alzheimer Disease's pathology

Descrizione del progetto

Uno strumento diagnostico per individuare l’insorgenza della malattia di Alzheimer

La malattia di Alzheimer non è curabile negli stadi finali, ma il rilevamento e il trattamento precoci potrebbero fornire benefici terapeutici e sociali significativi. Il trattamento svolto nelle fasi iniziali potrebbe rallentare o addirittura curare il morbo di Alzheimer, riducendo drasticamente i costi sanitari. L’azienda norvegese Pre Diagnostics sta lavorando per creare uno strumento diagnostico che identifichi i pazienti nelle primissime fasi della malattia, prima che la malattia di Alzheimer sia evidente. Questo strumento accurato ed economico di rilevamento attraverso biomarcatori ematici analizzerà direttamente il metabolismo cerebrale dei pazienti e individuerà l’eliminazione ridotta di beta-amiloide, il primissimo segnale nella malattia di Alzheimer. Il progetto VERDAD, finanziato dall’UE, fornirà supporto per le fasi normative finali nello sviluppo del nuovo strumento e lo preparerà per il mercato.

Obiettivo

Alzheimer’s Disease (AD) poses an unbearable impact in patients’ life, through progressive loss of cognitive capacities and overall quality of life. In Europe alone, there is currently a €280 bn yearly expenditure related to AD and ~10% of the population above 65 years old is currently affected by the disease, a figure that is expected to triple in the immediate future.
No treatment alternatives are available for AD patients with diagnosed disease and the existing diagnostic tools are very time consuming and expensive (6 months / 10.000 EUR). While AD is not curable at final stages of disease, detection at early stages offer several treatment alternatives for example through counseling and/or dietary interventions.
Detection and treatment of AD in its initial stages could provide major therapeutic and societal benefits. Treatment strategies at early stages could either slow down or even cure AD which would dramatically reduce the health care costs.
PreDiagnostics will exploit and transfer research knowledge developed by its founders to a commercial setting and provide a diagnostic tool to identify patients at early stages before disease is evident. Through the VERDAD project, PreDiagnostics will finalize the final regulatory steps and introduce into the market a novel, accurate and cost-effective blood biomarker detection tool. This tool directly analyses the patients’ brain metabolism and detects reduced clearance of beta-amyloid which is the first step in AD pathology.
The VERDAD project will allow for market introduction of a disruptive diagnostic test to identify AD decades before clinical signs are visible. This will facilitate early disease diagnosis and implementation of prevention strategies in likely patients. We have developed necessary collaborations to roll-out our diagnostic tool which will lead to major costs saving for the Health Care sector, generate new employment opportunities and in unlock a revenue stream of over €1.5bn 10-years post-Project.

Campo scientifico

Programma(i)

Argomento(i)

EIC-SMEInst-2018-2020 - SME instrument

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-2

Meccanismo di finanziamento

SME-2 - SME instrument phase 2

Coordinatore

PRE DIAGNOSTICS AS

Contribution nette de l'UE

€ 2 355 791,00

Indirizzo

Skogfaret 25 b
0382 Oslo
Norvegia

PMI

Sì

Regione

Norge Oslo og Viken Oslo

Tipo di attività

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Collegamenti

Contatta l’organizzazione

Partecipazione a programmi di R&I dell'UE

Rete di collaborazione HORIZON

Altri finanziamenti

€ 1 009 625,25